Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | August 27, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date August 27, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,000 |
Reported balance
After 2026-08-27 transaction · row 1
1 source rowRow 1 · 2026-08-27 · Gift · Disposed 6,000 · Balance 39,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2021 Filed Oct 18, 2021 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 240.293 | $182.07 | $43,750.15 |
DisclosureSEC source: 0001209191-21-060705 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,482.599 Underlying: Common Stock · 240.293 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 15,000 | $197.91 | $2,968,650.00 |
DisclosureSEC source: 0001209191-21-049602 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,210 F1 · price: Open market sales reported on this line occurred at a weighted average price of $197.91 (range $197.45 to $198.12). F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 220.96 | $198.00 | $43,750.08 |
DisclosureSEC source: 0001209191-21-046903 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,242.306 Underlying: Common Stock · 220.96 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 6,067 | $0.00 Strike: $217.20 | $0.00 |
DisclosureSEC source: 0001209191-21-029869 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Underlying: Common Stock · 6,067 shares Expires 2031-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 198.711 | $220.17 | $43,750.20 |
DisclosureSEC source: 0001209191-21-026943 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,021.346 Underlying: Common Stock · 198.711 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 193.593 | $225.99 | $43,750.08 |
DisclosureSEC source: 0001209191-21-004033 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,822.635 Underlying: Common Stock · 193.593 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 13:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 3,905 | $218.79 | $854,374.95 |
DisclosureSEC source: 0001209191-20-057828 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,210 F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. F4 · price: Open market purchases reported on this line occurred at a weighted average price of $218.79 (range $218.21 to $219.00). Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 13:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 4,270 | $217.49 | $928,682.30 |
DisclosureSEC source: 0001209191-20-057828 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,305 F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. F3 · price: Open market purchases reported on this line occurred at a weighted average price of $217.49 (range $217.05 to $218.04). Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 13:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 6,825 | $216.47 | $1,477,407.75 |
DisclosureSEC source: 0001209191-20-057828 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,035 F1 · price: Open market purchases reported on this line occurred at a weighted average price of $216.47 (range $216.01 to $217.00). F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 196.356 | $222.81 | $43,750.08 |
DisclosureSEC source: 0001209191-20-055264 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,629.042 Underlying: Common Stock · 196.356 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 155.253 | $292.77 | $45,453.42 |
DisclosureSEC source: 0001209191-20-042801 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,432.686 Underlying: Common Stock · 155.253 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 4,527 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034049 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,527 Underlying: Common Stock · 4,527 shares Expires 2030-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · derivative · entry 10 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · derivative · entry 9 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,960 | $272.46 | $806,481.60 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · nonDerivative · entry 8 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $272.46 (range $272.21 to $272.94). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,232 | $271.63 | $1,692,798.16 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · nonDerivative · entry 7 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,170 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $271.63 (range $271.17 to $272.14). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,889 | $270.49 | $1,592,915.61 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · nonDerivative · entry 6 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,402 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $270.49 (range $270.09 to $271.08). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,751 | $269.53 | $4,245,367.03 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · nonDerivative · entry 5 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,291 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $269.53 (range $269.06 to $270.04). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,568 | $268.65 | $3,107,743.20 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · nonDerivative · entry 4 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,042 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $268.65 (range $268.06 to $269.03). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,600 | $267.50 | $695,500.00 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,610 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $267.50 (range $267.06 to $268.03). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 22,500 | $81.54 | $1,834,650.00 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 22,500 | $59.55 | $1,339,875.00 |
DisclosureSEC source: 0001209191-20-027901 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 178.876 | $258.56 | $46,250.18 |
DisclosureSEC source: 0001209191-20-024786 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,277.433 Underlying: Common Stock · 178.876 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · derivative · entry 14 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $235.40 | $23,540.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 13 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $234.15 | $210,735.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 12 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,310 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13 · price: Open market sales reported on this line occurred at a weighted average price of $234.15 (range $233.77 to $234.66). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,800 | $233.13 | $419,634.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 11 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $233.13 (range $232.69 to $233.49). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $232.04 | $278,448.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 10 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,010 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.45 to $232.42). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $230.87 | $277,044.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 9 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $230.87 (range $230.32 to $231.23). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $229.90 | $114,950.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 8 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,410 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $229.90 (range $229.16 to $230.12). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $228.33 | $136,998.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 7 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $228.33 (range $227.97 to $228.78). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $227.66 | $68,298.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 6 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,510 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $227.66 (range $227.62 to $227.70). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,644 | $227.01 | $1,281,244.44 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 5 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $227.01 (range $226.70 to $227.59). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,198 | $226.32 | $950,091.36 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 4 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,454 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $226.32 (range $225.62 to $226.60). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,858 | $224.98 | $418,012.84 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,652 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $224.98 (range $224.66 to $225.21). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,700 | $224.02 | $380,834.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,510 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $224.02 (range $223.58 to $224.40). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $53.85 | $1,077,000.00 |
DisclosureSEC source: 0001209191-20-006298 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 199.741 | $231.55 | $46,250.03 |
DisclosureSEC source: 0001209191-20-003955 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,098.557 Underlying: Common Stock · 199.741 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 263.533 | $175.50 | $46,250.04 |
DisclosureSEC source: 0001209191-19-053410 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,898.816 Underlying: Common Stock · 263.533 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 20:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 257.22 | $176.39 | $45,371.04 |
DisclosureSEC source: 0001209191-19-042388 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,635.283 Underlying: Common Stock · 257.22 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 1,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-034242 · doc4.xml · derivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,378.063 Underlying: Common Stock · 1,801 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs's disability or death. F1 · price: Upon the vesting of restricted stock units granted to Mr. Sachs on June 1, 2018, Mr. Sachs deferred the receipt of 1,801 shares of common stock and received instead 1,801 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Mr. Sachs is reporting the disposition of 1,801 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs's disability or death. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 6,659 | $0.00 Strike: $168.04 | $0.00 |
DisclosureSEC source: 0001209191-19-034242 · doc4.xml · derivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,659 Underlying: Common Stock · 6,659 shares Expires 2029-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 1,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-034242 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,210 F1 · price: Upon the vesting of restricted stock units granted to Mr. Sachs on June 1, 2018, Mr. Sachs deferred the receipt of 1,801 shares of common stock and received instead 1,801 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Mr. Sachs is reporting the disposition of 1,801 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 246.873 | $182.28 | $45,000.01 |
DisclosureSEC source: 0001209191-19-025000 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,577.063 Underlying: Common Stock · 246.873 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 243.375 | $184.90 | $45,000.04 |
DisclosureSEC source: 0001209191-19-003955 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,330.19 Underlying: Common Stock · 243.375 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 21:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000315 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,011 F1 · kind: Represents a gift to a charitable foundation. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0001209191-18-061479 · doc4.xml · derivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $34.24 | $342,400.00 |
DisclosureSEC source: 0001209191-18-061479 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 13:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 250.991 | $179.29 | $45,000.18 |
DisclosureSEC source: 0001209191-18-055214 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086.815 Underlying: Common Stock · 250.991 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 248.66 | $180.97 | $45,000.00 |
DisclosureSEC source: 0001209191-18-043122 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,835.824 Underlying: Common Stock · 248.66 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.